A plethora of reports have highlighted that FAK’s expression levels and its activation correlate with the initiation, progression, and the prognosis of a wide variety of malignancies, and, thus, FAK has been repeatedly proposed as an attractive target for cancer therapy2–4,6,7,20. The gene discussed is PTK2; the disease is cancer.